Effector and regulatory B cells in Multiple Sclerosis

Effector and regulatory B cells in Multiple Sclerosis

Copyright © 2017 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 184(2017) vom: 10. Nov., Seite 11-25
1. Verfasser: Staun-Ram, Elsebeth (VerfasserIn)
Weitere Verfasser: Miller, Ariel
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2017
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Review Autoimmune B cells Bregs Immune-modulation Immunotherapy Multiple Sclerosis Crotonates Hydroxybutyrates mehr... Immunologic Factors Immunosuppressive Agents Natalizumab Nitriles Toluidines teriflunomide 1C058IKG3B Alemtuzumab 3A189DH42V Rituximab 4F4X42SYQ6 Glatiramer Acetate 5M691HL4BO Interferon-beta 77238-31-4 Dimethyl Fumarate FO2303MNI2 Fingolimod Hydrochloride G926EC510T
LEADER 01000naa a22002652 4500
001 NLM271469153
003 DE-627
005 20231224232753.0
007 cr uuu---uuuuu
008 231224s2017 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2017.04.014  |2 doi 
028 5 2 |a pubmed24n0904.xml 
035 |a (DE-627)NLM271469153 
035 |a (NLM)28461106 
035 |a (PII)S1521-6616(16)30556-3 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Staun-Ram, Elsebeth  |e verfasserin  |4 aut 
245 1 0 |a Effector and regulatory B cells in Multiple Sclerosis 
264 1 |c 2017 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 16.11.2017 
500 |a Date Revised 21.03.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2017 Elsevier Inc. All rights reserved. 
520 |a The role of B cells in the pathogenesis of Multiple Sclerosis (MS), an autoimmune neurodegenerative disease, is becoming eminent in recent years, but the specific contribution of the distinct B cell subsets remains to be elucidated. Several B cell subsets have shown regulatory, anti-inflammatory capacities in response to stimuli in vitro, as well as in the animal model of MS: Experimental Autoimmune Encephalomyelitis (EAE). However, the functional role of the B regulatory cells (Bregs) in vivo and specifically in the human disease is yet to be clarified. In the present review, we have summarized the updated information on the roles of effector and regulatory B cells in MS and the immune-modulatory effects of MS therapeutic agents on their phenotype and function 
650 4 |a Journal Article 
650 4 |a Review 
650 4 |a Autoimmune 
650 4 |a B cells 
650 4 |a Bregs 
650 4 |a Immune-modulation 
650 4 |a Immunotherapy 
650 4 |a Multiple Sclerosis 
650 7 |a Crotonates  |2 NLM 
650 7 |a Hydroxybutyrates  |2 NLM 
650 7 |a Immunologic Factors  |2 NLM 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a Natalizumab  |2 NLM 
650 7 |a Nitriles  |2 NLM 
650 7 |a Toluidines  |2 NLM 
650 7 |a teriflunomide  |2 NLM 
650 7 |a 1C058IKG3B  |2 NLM 
650 7 |a Alemtuzumab  |2 NLM 
650 7 |a 3A189DH42V  |2 NLM 
650 7 |a Rituximab  |2 NLM 
650 7 |a 4F4X42SYQ6  |2 NLM 
650 7 |a Glatiramer Acetate  |2 NLM 
650 7 |a 5M691HL4BO  |2 NLM 
650 7 |a Interferon-beta  |2 NLM 
650 7 |a 77238-31-4  |2 NLM 
650 7 |a Dimethyl Fumarate  |2 NLM 
650 7 |a FO2303MNI2  |2 NLM 
650 7 |a Fingolimod Hydrochloride  |2 NLM 
650 7 |a G926EC510T  |2 NLM 
700 1 |a Miller, Ariel  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 184(2017) vom: 10. Nov., Seite 11-25  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:184  |g year:2017  |g day:10  |g month:11  |g pages:11-25 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2017.04.014  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 184  |j 2017  |b 10  |c 11  |h 11-25